Navigation Links
ResearchDx Appointment of New Chief Medical Officer to Meet NIH Push for Precision Medicine in Expediting Bench to Bedside" Strategies for Disease Treatment
Date:12/7/2015

Internationally recognized as the "Contract Diagnostics Organization," ResearchDx specializes in the development of companion and in vitro diagnostics for the pharmaceutical, biotechnology, research, and diagnostic industries. To meet the demand for leveraging new technology and increase the speed at which new treatments reach patients, life sciences firm ResearchDx has appointed Shelly Gunn MD, PhD, FCAP as Chief Medical Officer and Medical Director of their CAP/CLIA certified clinical laboratory, Pacific Diagnostics.

Dr. Gunn's addition at ResearchDx and clinical laboratory, Pacific Diagnostics will expand the company's capabilities in the growing disciplines of Translational and Precision Medicine. Translational medicine aims to expedite the discovery of new diagnostic tools and treatments by using a multi-disciplinary, highly collaborative, "bench-to-bedside" approach. Precision medicine is an emerging approach for disease prevention and treatments individualized to variations in each person’s genes, environment, and lifestyle. https://www.nih.gov/precision-medicine-initiative-cohort-program.

The National Institutes of Health (NIH) has made a major push to fund translational and precision medicine, especially within biomedical research, with a focus on cross-functional collaborations (e.g., between researchers and clinicians); leveraging new technology and data analysis tools, and increasing the speed at which new treatments reach patients.

"I am delighted to be joining the globally recognized Contract Diagnostics Organization and look forward to working with the team in Irvine to promote continued excellence in the development of companion diagnostic assays for pharma, biotech, and the medical community. As Chief Medical Officer and Medical Director of our CAP/CLIA accredited laboratory, Pacific Diagnostics, I plan to rapidly translate new and innovative technologies from the research bench into clinically available patient testing for cancer, chronic disease, and wellness,” says Dr. Gunn.

A distinguished expert in molecular pathology, Dr. Gunn specializes in genomic biomarker identification for breast cancer and other solid tumors. Dr. Gunn’s Boards, Licensures, and Certifications include the American Board of Pathology, Certified in Clinical Pathology; Texas, New York, and California licensure, as well as a New York State Certificate of Qualification in Molecular and Cellular Tumor Markers.

For more information on the biopharma companion diagnostic test development process, translational, or precision medicine, please contact media representative Vicki Garcia at 619-660-6730.

Read the full story at http://www.prweb.com/releases/2015/11/prweb13094313.htm.


'/>"/>
Source: PRWeb
Copyright©2015 Vocus, Inc.
All rights reserved


Related biology technology :

1. TaxOps Announces Partner Appointment to Prominent International Position with Fortune 100 Company
2. National Honey Board Seeks Board Member Nominees: Appointments to be Made by United States Secretary of Agriculture
3. Appointment of Mr. Kevin Buchi to Benitec Board
4. Veracyte Announces Appointment of Shelly D. Guyer as Chief Financial Officer
5. Taylor-Wharton™ Announces Recent Appointments in its Global Operations
6. Arthritis Foundation Announces Appointment of John Vernachio As Vice President of Research
7. Emerson Resources Announces CEO Retirement and Appointment of Successor
8. Cellular Biomedicine Group Announces Appointment of Corporate Controller
9. Verenium Announces Appointment Of Brian Carter As Vice President Of Grain Processing
10. inVentiv Health Clinical Expands and Strengthens Executive Team with Three Strategic Appointments
11. Epic Sciences Announces Appointment of Dr. Murali Prahalad as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2018)... ... September 20, 2018 , ... ... venture. The synergistic combination of Predicine’s GeneRADAR molecular insights platform with Flagship’s ... to empower clinical trials in the immuno-oncology (IO) space. , IO therapies ...
(Date:9/13/2018)... ... September 13, 2018 , ... Asymmetrex’s director, ... we would have gotten in medicine, if we didn’t have the means to measure ... treat patients?” His answer, “Nowhere! And that is what’s holding up progress in ...
(Date:9/7/2018)... ... September 05, 2018 , ... Now available on live stream, the ... on Sept. 19, 2018. With a panel of industry leaders from Harvard, Cornell, RPI, ... reveal industry insights from experts in the field. Register today to be a ...
(Date:9/1/2018)... , ... August 31, 2018 , ... ... results of the impact of a proprietary biofield energy treated nutraceutical supplement used ... biomarkers for immune function response and blood, as well as, organ-specific inflammation. The ...
Breaking Biology Technology:
(Date:8/23/2018)... (PRWEB) , ... August 22, 2018 , ... ... release of LimitLIS® 4.0, the latest version of its rapidly growing cloud-based laboratory ... LimitLIS® Toxicology Edition, as well as the company’s triple digit growth throughout 2018, ...
(Date:8/21/2018)... ... August 20, 2018 , ... ... are many challenges to consider. Designers must ensure what is designed can be ... will explore some best practices in flow path design with specific focus on ...
(Date:8/21/2018)... ... August 21, 2018 , ... Whether it ... Labs is dedicated to offering customers a successful experience. When browsing the ... seamless transition between products, with relevant details such as technical manuals, application notes, ...
Breaking Biology News(10 mins):